AIM
NVCR icon

Advantage Investment Management’s NovoCure NVCR Stock Holding History

Advantage Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-500
Closed -$17K – 986
2018
Q4 		$17K Sell
500
-185
-27% -$6.76K 0.01% 544
2018
Q3 		$36K Buy
685
+185
+37% +$7.36K 0.02% 454
2018
Q2 		$16K Hold
500
– – 0.01% 585
2018
Q1 		$11K Hold
500
– – ﹤0.01% 664
2017
Q4 		$10K Hold
500
– – ﹤0.01% 690
2017
Q3 		$10K Buy
+500
New +$9.83K ﹤0.01% 690

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Advantage Investment Management's NVCR Position: Q1 2019 in Review

Advantage Investment Management sold out of NovoCure (NVCR) in Q1 2019, closing a stake of 500 shares — an estimated $17K sold.

Advantage Investment Management first reported a position in NVCR in Q3 2017 and held it in 6 quarters. The position peaked at $36K in Q3 2018. 200 funds tracked by Wall St. Rank hold NVCR as of Q1 2019.

  • Advantage Investment Management reported no remaining NovoCure position as of Q1 2019 after selling out during the quarter.
  • Advantage Investment Management sold 500 NovoCure shares in Q1 2019, an estimated $17K.
  • Advantage Investment Management first reported a position in NovoCure in Q3 2017 and held it in 6 quarters.
  • Advantage Investment Management's NovoCure position peaked at $36K in Q3 2018.
  • 200 funds tracked by Wall St. Rank held NovoCure as of Q1 2019.

Based on Advantage Investment Management's 13F filing for Q1 2019, filed 15 May 2019.